The weight loss achieved varies by medication: liraglutide typically produces 5-8% weight loss, semaglutide approximately 15%, and tirzepatide up to 21% of initial body weight
SURMOUNT-4 The fourth study of the program, SURMOUNT-4, was designed to evaluate the efficacy of tirzepatide in weight loss maintenance in adult patients with a BMI 30 or 27 with an associated complication, but no T2D
Both medications most commonly produce gastrointestinal symptoms: nausea, vomiting, diarrhea and constipation
Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials
Another prospective clinical study found that exosome therapy combined with microneedling produced an average increase of 35 hairs per square centimeter at 12 months, with 87% of patients reporting satisfaction with their results
Nutritional and therapeutic potential of spirulina